Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus concurrent chemoradiotherapy for locally advanced cervical cancer
ChiCTR1800017356Phase 2Not yet recruiting
- Sponsor
- Liuzhou People's Hospital
- Start
- Sep 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in Cervical Cancer (CC) (2 arms), sponsored by Liuzhou People's Hospital. Primary endpoints: Progression-free survival and Overall survival. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800017356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017356.